RESUMO
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (n = 17) and polycythemia vera (n = 15) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47 AU/mL vs 217.97 AU/mL, p = 0.003 and 60% vs 93.8%, p = 0.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (p = 0.076), though large prospective study is needed to address this issue.
Assuntos
Anticorpos Antivirais/sangue , Tratamento Farmacológico da COVID-19 , Vacinas contra COVID-19/administração & dosagem , Policitemia Vera/imunologia , Mielofibrose Primária/imunologia , SARS-CoV-2/efeitos dos fármacos , Trombocitemia Essencial/imunologia , Idoso , Anticorpos Antivirais/imunologia , Vacina BNT162 , COVID-19/complicações , COVID-19/virologia , Feminino , Humanos , Masculino , Policitemia Vera/patologia , Policitemia Vera/virologia , Mielofibrose Primária/patologia , Mielofibrose Primária/virologia , Prognóstico , Trombocitemia Essencial/patologia , Trombocitemia Essencial/virologiaAssuntos
Doenças do Gato/diagnóstico , Leucemia Felina/diagnóstico , Trombocitemia Essencial/veterinária , Animais , Doenças do Gato/sangue , Gatos , Diagnóstico Diferencial , Evolução Fatal , Vírus da Leucemia Felina/isolamento & purificação , Leucemia Felina/sangue , Masculino , Trombocitemia Essencial/sangue , Trombocitemia Essencial/diagnóstico , Trombocitemia Essencial/virologiaRESUMO
OBJECTIVE: The aim of this study was to determine the extent of human endogenous retrovirus (HERV) gene translation in megakaryocytes cultured from peripheral blood stem cells of patients with essential thrombocythemia previously reported with platelet-associated HERV sequences and reverse transcriptase activity. MATERIALS AND METHODS: Terminally differentiated megakaryocytes derived from circulating stem cells in serum-free medium supplemented with stem cell factor and thrombopoietin were processed for electron microscopic immunostaining using a monoclonal antibody against the gag protein of HERV-K10 and an electron dense gold-labeled secondary antibody. RESULTS: We found that HERV-K gag protein was detected as clusters in the cytoplasm as well as associated with viral particles budding from the cell membrane and into intracellular vacuoles in megakaryocytes from two patients with essential thrombocythemia. None of these structures was observed in megakaryocytes from a normal control or from a patient with chronic myelocytic leukemia. CONCLUSION: This is the first evidence of HERV-K protein synthesis (gene translation) in human tissue other than seminomas, placenta, or fetal tissue. Translation of the HERV-K gag gene with subsequent packaging of the protein product into viral particles adds a new and important dimension to future studies on the role of HERVs in the myeloproliferative diseases.
